Search

Your search keyword '"Al-Emadi S"' showing total 14 results
Start Over Author "Al-Emadi S" Journal annals of the rheumatic diseases
14 results on '"Al-Emadi S"'

3. OP0286 CHARACTERISTICS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE (COVID-19 GRA)

Author

Ugarte-Gil, M. F., primary, Alarcon, G. S., additional, Seet, A., additional, Izadi, Z., additional, Reategui Sokolova, C., additional, Clarke, A. E., additional, Wise, L., additional, Pons-Estel, G., additional, Santos, M. J., additional, Bernatsky, S., additional, Mathias, L., additional, Lim, N., additional, Sparks, J., additional, Wallace, Z., additional, Hyrich, K., additional, Strangfeld, A., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Lawson-Tovey, S., additional, Trupin, L., additional, Rush, S., additional, Schmajuk, G., additional, Katz, P., additional, Jacobsohn, L., additional, Al Emadi, S., additional, Gilbert, E., additional, Duarte-Garcia, A., additional, Valenzuela-Almada, M., additional, Hsu, T., additional, D’silva, K., additional, Serling-Boyd, N., additional, Dieudé, P., additional, Nikiphorou, E., additional, Kronzer, V., additional, Singh, N., additional, Wallace, B., additional, Akpabio, A., additional, Thomas, R., additional, Bhana, S., additional, Costello, W., additional, Grainger, R., additional, Hausmann, J., additional, Liew, J., additional, Sirotich, E., additional, Sufka, P., additional, Robinson, P., additional, Machado, P., additional, Gianfrancesco, M., additional, and Yazdany, J., additional

Published
2021
Full Text
View/download PDF

4. OP0288 MACHINE LEARNING ALGORITHMS TO PREDICT COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME IN PATIENTS WITH RHEUMATIC DISEASES: RESULTS FROM THE GLOBAL RHEUMATOLOGY ALLIANCE PROVIDER REGISTRY

Author

Izadi, Z., primary, Gianfrancesco, M., additional, Hyrich, K., additional, Strangfeld, A., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Lawson-Tovey, S., additional, Trupin, L., additional, Rush, S., additional, Schmajuk, G., additional, Jacobsohn, L., additional, Katz, P., additional, Al Emadi, S., additional, Wise, L., additional, Gilbert, E., additional, Valenzuela-Almada, M., additional, Duarte-Garcia, A., additional, Sparks, J., additional, Hsu, T., additional, D’silva, K., additional, Serling-Boyd, N., additional, Bhana, S., additional, Costello, W., additional, Grainger, R., additional, Hausmann, J., additional, Liew, J., additional, Sirotich, E., additional, Sufka, P., additional, Wallace, Z., additional, Machado, P., additional, Robinson, P., additional, and Yazdany, J., additional

Published
2021
Full Text
View/download PDF

5. AB0104 CONCORDANCE BETWEEN THE PHYSICIAN’S AND THE PATIENT’S ASSESSMENT OF DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS: RESULTS OF THE AUTODAS-MEAC STUDY AT ONE YEAR

Author

Ziade, N., primary, Al Emadi, S., additional, Abu Jbara, M., additional, Saad, S., additional, Kibbi, L., additional, Merheb, G., additional, Badsha, H., additional, Harifi, G., additional, Alam, E., additional, Ayko, A., additional, Zorkany, B., additional, Daher, A., additional, Halabi, H., additional, Mashaleh, M., additional, Masri, B., additional, Messaykeh, J., additional, Mroue’, K., additional, Salloum, N., additional, and Arayssi, T., additional

Published
2021
Full Text
View/download PDF

6. POS0275-HPR CONCORDANCE BETWEEN THE PHYSICIAN’S AND THE NURSE’S ASSESSMENT OF DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS USING DAS-28, CDAI AND SDAI IN SEVEN MIDDLE EASTERN ARAB COUNTRIES

Author

Ziade, N., primary, Zorkany, B., additional, Al Emadi, S., additional, Abu Jbara, M., additional, Halabi, H., additional, Saad, S., additional, Kibbi, L., additional, Mashaleh, M., additional, Badsha, H., additional, Harifi, G., additional, Ayko, A., additional, Alam, E., additional, Daher, A., additional, Masri, B., additional, Merheb, G., additional, Messaykeh, J., additional, Mroue’, K., additional, Salloum, N., additional, and Arayssi, T., additional

Published
2021
Full Text
View/download PDF

7. OP0006 ASSOCIATIONS OF BASELINE USE OF BIOLOGIC OR TARGETED SYNTHETIC DMARDS WITH COVID-19 SEVERITY IN RHEUMATOID ARTHRITIS: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE

Author

Sparks, J., primary, Wallace, Z., additional, Seet, A., additional, Gianfrancesco, M., additional, Izadi, Z., additional, Hyrich, K., additional, Strangfeld, A., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Lawson-Tovey, S., additional, Trupin, L., additional, Rush, S., additional, Schmajuk, G., additional, Katz, P., additional, Jacobsohn, L., additional, Al Emadi, S., additional, Wise, L., additional, Gilbert, E., additional, Duarte-Garcia, A., additional, Valenzuela-Almada, M., additional, Hsu, T., additional, D’silva, K., additional, Serling-Boyd, N., additional, Dieudé, P., additional, Nikiphorou, E., additional, Kronzer, V., additional, Singh, N., additional, Ugarte-Gil, M. F., additional, Wallace, B., additional, Akpabio, A., additional, Thomas, R., additional, Bhana, S., additional, Costello, W., additional, Grainger, R., additional, Hausmann, J., additional, Liew, J., additional, Sirotich, E., additional, Sufka, P., additional, Robinson, P., additional, Machado, P., additional, and Yazdany, J., additional

Published
2021
Full Text
View/download PDF

8. FRI0061 THE ADVERSE OBSTETRIC OUTCOMES WHEN RHEUMATOID ARTHRITIS IS CONTROLLED DURING PREGNANCY: IS THE DISEASE ITSELF A PROBLEM? DATA FROM A CASE-CONTROL COHORT OF 190 PREGNANCIES AT A MULTI-NATIONALITY SPECIALIZED CENTER IN QATAR

Author

Elsayed, E., primary, Abuyaqoub, S., additional, Almallahi, N., additional, Alam, F., additional, Saleh, R., additional, Chandra, P., additional, Almulla, N., additional, Al Kahlout, M., additional, Hamed, M., additional, Abdulla, N., additional, and Al Emadi, S., additional

Published
2020
Full Text
View/download PDF

13. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Author

Maria Margarida Cunha, Gabriela Schmajuk, Rebecca Hasseli, Namrata Singh, Tiffany Y.T. Hsu, Milena A. Gianfrancesco, Anja Strangfeld, Ranjeny Thomas, Naomi J Patel, Thierry Thomas, Philippe Dieudé, Kimme L. Hyrich, Emily Sirotich, Laura Trupin, Liselotte Tidblad, Jinoos Yazdany, René Marc Flipo, Licia Maria Henrique da Mota, Andrea M Seet, Samar Al Emadi, Carolina A. Isnardi, Saskia Lawson-Tovey, Alí Duarte-García, Hendrik Schulze-Koops, Manuel F. Ugarte-Gil, Vanessa L. Kronzer, Philip Robinson, Lindsay Jacobsohn, Elsa F Mateus, Pedro Machado, Ana Paula Monteiro Gomides, Jean W. Liew, Guillermo A. Berbotto, Miguel Bernardes, Patricia P. Katz, Martin Schäfer, Guillermo J. Pons-Estel, Ulf Müller-Ladner, Jeffrey A. Sparks, Elena Nikiphorou, Christof Specker, Paul Sufka, Zara Izadi, Loreto Carmona, Stephanie Rush, Sandra Lúcia Euzébio Ribeiro, Maria O Valenzuela-Almada, Kristin M. D’Silva, Emily L Gilbert, Raphaèle Seror, Laure Gossec, Beth I Wallace, Viviane Angelina de Souza, Akpabio Akpabio, Jérôme Avouac, Leanna Wise, Wendy Costello, Zachary S. Wallace, Suleman Bhana, Jonathan S. Hausmann, Lianne Kearsley-Fleet, Bernd Raffeiner, Carlo Alberto Scirè, Rebecca Grainger, Sparks, J, Wallace, Z, Seet, A, Gianfrancesco, M, Izadi, Z, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Lawson-Tovey, S, Trupin, L, Rush, S, Katz, P, Schmajuk, G, Jacobsohn, L, Wise, L, Gilbert, E, Duarte-Garcia, A, Valenzuela-Almada, M, Pons-Estel, G, Isnardi, C, Berbotto, G, Hsu, T, D'Silva, K, Patel, N, Kearsley-Fleet, L, Schafer, M, Ribeiro, S, Al Emadi, S, Tidblad, L, Scire, C, Raffeiner, B, Thomas, T, Flipo, R, Avouac, J, Seror, R, Bernardes, M, Cunha, M, Hasseli, R, Schulze-Koops, H, Muller-Ladner, U, Specker, C, De Souza, V, Da Mota, L, Gomides, A, Dieude, P, Nikiphorou, E, Kronzer, V, Singh, N, Ugarte-Gil, M, Wallace, B, Akpabio, A, Thomas, R, Bhana, S, Costello, W, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Sufka, P, Robinson, P, Machado, P, and Yazdany, J

Subjects
Male, medicine.medical_specialty, abatacept, Coronavirus disease 2019 (COVID-19), Immunology, tumour necrosis factor inhibitors, tumour necrosis factor inhibitor, Antirheumatic Agents/therapeutic use, Rheumatoid Arthritis, Severity of Illness Index, General Biochemistry, Genetics and Molecular Biology, Arthritis, Rheumatoid, 03 medical and health sciences, 0302 clinical medicine, rituximab, Rheumatology, Arthritis, Rheumatoid/complications, Internal medicine, medicine, Immunology and Allergy, Humans, 030212 general & internal medicine, Registries, Interleukin 6, Aged, 030203 arthritis & rheumatology, biology, business.industry, SARS-CoV-2, Abatacept, Confounding, COVID-19, rheumatoid arthriti, Middle Aged, medicine.disease, Drug class, Rheumatoid arthritis, Antirheumatic Agents, COVID-19/complications, biology.protein, Rituximab, Female, business, medicine.drug
Abstract

ObjectiveTo investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA).MethodsWe analysed the COVID-19 Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021). We investigated b/tsDMARD use for RA at the clinical onset of COVID-19 (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 inhibitors (IL-6i) or tumour necrosis factor inhibitors (TNFi, reference group). The ordinal COVID-19 severity outcome was (1) no hospitalisation, (2) hospitalisation without oxygen, (3) hospitalisation with oxygen/ventilation or (4) death. We used ordinal logistic regression to estimate the OR (odds of being one level higher on the ordinal outcome) for each drug class compared with TNFi, adjusting for potential baseline confounders.ResultsOf 2869 people with RA (mean age 56.7 years, 80.8% female) on b/tsDMARD at the onset of COVID-19, there were 237 on ABA, 364 on RTX, 317 on IL-6i, 563 on JAKi and 1388 on TNFi. Overall, 613 (21%) were hospitalised and 157 (5.5%) died. RTX (OR 4.15, 95% CI 3.16 to 5.44) and JAKi (OR 2.06, 95% CI 1.60 to 2.65) were each associated with worse COVID-19 severity compared with TNFi. There were no associations between ABA or IL6i and COVID-19 severity.ConclusionsPeople with RA treated with RTX or JAKi had worse COVID-19 severity than those on TNFi. The strong association of RTX and JAKi use with poor COVID-19 outcomes highlights prioritisation of risk mitigation strategies for these people.

Published
2021
Full Text
View/download PDF

14. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance.

Author

Ugarte-Gil MF, Alarcón GS, Izadi Z, Duarte-García A, Reátegui-Sokolova C, Clarke AE, Wise L, Pons-Estel GJ, Santos MJ, Bernatsky S, Ribeiro SLE, Al Emadi S, Sparks JA, Hsu TY, Patel NJ, Gilbert EL, Valenzuela-Almada MO, Jönsen A, Landolfi G, Fredi M, Goulenok T, Devaux M, Mariette X, Queyrel V, Romão VC, Sequeira G, Hasseli R, Hoyer B, Voll RE, Specker C, Baez R, Castro-Coello V, Maldonado Ficco H, Reis Neto ET, Ferreira GAA, Monticielo OAA, Sirotich E, Liew J, Hausmann J, Sufka P, Grainger R, Bhana S, Costello W, Wallace ZS, Jacobsohn L, Taylor T, Ja C, Strangfeld A, Mateus EF, Hyrich KL, Carmona L, Lawson-Tovey S, Kearsley-Fleet L, Schäfer M, Machado PM, Robinson PC, Gianfrancesco M, and Yazdany J

Subjects
Humans, Male, Prednisone therapeutic use, Severity of Illness Index, COVID-19, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic drug therapy, Rheumatology
Abstract

Aim: To determine characteristics associated with more severe outcomes in a global registry of people with systemic lupus erythematosus (SLE) and COVID-19., Methods: People with SLE and COVID-19 reported in the COVID-19 Global Rheumatology Alliance registry from March 2020 to June 2021 were included. The ordinal outcome was defined as: (1) not hospitalised, (2) hospitalised with no oxygenation, (3) hospitalised with any ventilation or oxygenation and (4) death. A multivariable ordinal logistic regression model was constructed to assess the relationship between COVID-19 severity and demographic characteristics, comorbidities, medications and disease activity., Results: A total of 1606 people with SLE were included. In the multivariable model, older age (OR 1.03, 95% CI 1.02 to 1.04), male sex (1.50, 1.01 to 2.23), prednisone dose (1-5 mg/day 1.86, 1.20 to 2.66, 6-9 mg/day 2.47, 1.24 to 4.86 and ≥10 mg/day 1.95, 1.27 to 2.99), no current treatment (1.80, 1.17 to 2.75), comorbidities (eg, kidney disease 3.51, 2.42 to 5.09, cardiovascular disease/hypertension 1.69, 1.25 to 2.29) and moderate or high SLE disease activity (vs remission; 1.61, 1.02 to 2.54 and 3.94, 2.11 to 7.34, respectively) were associated with more severe outcomes. In age-adjusted and sex-adjusted models, mycophenolate, rituximab and cyclophosphamide were associated with worse outcomes compared with hydroxychloroquine; outcomes were more favourable with methotrexate and belimumab., Conclusions: More severe COVID-19 outcomes in individuals with SLE are largely driven by demographic factors, comorbidities and untreated or active SLE. Patients using glucocorticoids also experienced more severe outcomes., Competing Interests: Competing interests: MFU-G has received research grants from Pfizer and Janssen, not related to this manuscript. AD-G is supported by the Rheumatology Research Foundation (Scientist Development Award) and the Centers for Disease Control and Prevention. CR-S has received research grants from Janssen, not related to this manuscript. AEC has received consulting fees from AstraZeneca, BMS and GSK, all unrelated to this manuscript. LW has received consulting fees and speaker’s honoraria from Aurinia Pharma unrelated to this manuscript. GJP-E reports no competing interests related to this work. Outside of this work, he reports personal consulting and/or speaking fees from Pfizer, GSK, Janssen and Sanofi (all

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results